

Please try another search
Zealand Pharma A/S reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was DKK 13.63 million compared to DKK 10.96 million a year ago. Net loss was DKK 193.63 million compared to DKK 222.85 million a year ago. Basic loss per share from continuing operations was DKK 3.76 compared to DKK 2.2 a year ago. Basic loss per share was DKK 3.76 compared to DKK 5.16 a year ago.
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Revenue | 13.63 | 23.92 | 43.71 | 21.27 |
Gross Profit | -121.57 | 43.14 | 24.18 | |
Operating Income | -168.67 | -235.88 | -162.08 | -190.7 |
Net Income | -193.63 | -148.34 | -488.5 |
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Assets | 1340.51 | 1539.81 | 1091.61 | 1256.55 |
Total Liabilities | 667.27 | 723.9 | 725.17 | 751.61 |
Total Equity | 673.24 | 815.91 | 366.44 | 504.95 |
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -196.68 | -126.01 | -226.91 | |
Cash From Investing Activities | -64.85 | 102.69 | 77.17 | -192.85 |
Cash From Financing Activities | 30.16 | 765.93 | -23.59 | -151.48 |
Net Change in Cash | -238.16 | -59.49 | -569.99 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review